pyrazolanthrone has been researched along with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Ficarro, SB; Gray, NS; Inesta-Vaquera, F; Kim, N; Laughlin, JD; LoGrasso, PV; Machleidt, T; Marto, JA; Niepel, M; Nomanbhoy, TK; Park, H; Patricelli, M; Sim, T; Sorger, PK; Xie, T; Zhang, J; Zhang, T | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
2 other study(ies) available for pyrazolanthrone and N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide
| Article | Year |
|---|---|
Discovery of potent and selective covalent inhibitors of JNK.
Topics: Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Evaluation, Preclinical; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary | 2012 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |